Dominic Rodrigues - 30 Jun 2026 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Jun 2026, 21:22:03 UTC
Prior SEC filing
04 Dec 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dominic Rodrigues

Key filing fact

Dominic Rodrigues filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 30 Jun 2026.

Key facts

  • This page summarizes Dominic Rodrigues's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 30 Jun 2026, 21:22.

Change

  • Previous filing in this sequence was filed on 04 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001703719 Primary reporting owner

Rodrigues Dominic

Relationship
PRESIDENT, Director
Address
800 S. GAY STREET,, SUITE 1610, KNOXVILLE
Signature
/s/ Dominic Rodrigues
Signature date
30 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVCT transaction Derivative

Series D-1 Convertible Preferred Stock

Award

Transaction value
Shares
+45,860
Change %
+3.4%
Price
$0.000000*
Shares after
1,383,736
Date
30 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
458,600
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

Footnote F2

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .